Targeting IL-21 to tumor-reactive T cells enhances memory T cell responses and anti-PD-1 antibody therapy
The lack of an efficient anti-tumor T cell response contributes to the failure of anti-PD1 therapy. Here, the authors show a potential strategy to improve the therapeutic effects of anti-PD-1 antibody by simultaneously targeting IL-21 to tumor-reactive T cells in vivo.
Saved in:
Main Authors: | Ying Li, Yanni Cong, Mingming Jia, Qianqian He, Haiqing Zhong, Yun Zhao, Hang Li, Meining Yan, Jia You, Jia Liu, Lieping Chen, Haiying Hang, Shengdian Wang |
---|---|
Format: | article |
Language: | EN |
Published: |
Nature Portfolio
2021
|
Subjects: | |
Online Access: | https://doaj.org/article/e0144328845a498a9c1f543f87d37f7c |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Pre-transplant donor-reactive IL-21 producing T cells as a tool to identify an increased risk for acute rejection
by: Aleixandra Mendoza Rojas, et al.
Published: (2021) -
Memory B cells are reactivated in subcapsular proliferative foci of lymph nodes
by: Imogen Moran, et al.
Published: (2018) -
Anti-PD-1 Immunotherapy Combined With Stereotactic Body Radiation Therapy and GM-CSF as Salvage Therapy in a PD-L1-Positive Patient With Refractory Metastatic Thyroid Hürthle Cell Carcinoma: A Case Report and Literature Review
by: Haihua He, et al.
Published: (2021) -
IL-21 restricts T follicular regulatory T cell proliferation through Bcl-6 mediated inhibition of responsiveness to IL-2
by: Christoph Jandl, et al.
Published: (2017) -
Metformin Downregulates PD-L1 Expression in Esophageal Squamous Cell Catrcinoma by Inhibiting IL-6 Signaling Pathway
by: Yao Lu, et al.
Published: (2021)